Definiens Immunoprofiling Panel

The latest release of Genomenon's Mastermind Genomic Search Engine indexes approximately 500,000 new genomic variants from supplemental data found in scientific publications. Most precision medicine tools have not been able to provide insight into supplemental data without manual curation due to the lack of a common file format, the company noted. Supplemental data is often published as an Excel, PDF, .csv, Word, text, or image file. Genomenon said that it overcame this challenge by engineering its indexing pipeline to ingest these different file formats and applying its proprietary Genomic Language Processing technology to index the content for easy retrieval by researchers. 

Roche has launched two Navify clinical decision support apps, Navify Clinical Trial Match and Navify Publication Search, to help oncologists access clinical trial information and publications. Both are available on the Navify Tumor Board platform.

The Navify Clinical Trial Match app identifies clinical trial options from 11 international registries, based on patient-specific attributes such as age, sex, biomarkers, and various tumor attributes. The registries include ClinicalTrials.gov, the German Clinical Trials Registry, and the European Clinical Trials Registry. The Navify Publication Search app mines several publication sources, including PubMed, the American Society of Clinical Oncology, and the American Association of Central Cancer Registries, for relevant literature. The content of both apps is provided by MolecularMatch, a clinical informatics company.

Roche said it plans to add more apps, including from partners and third parties, in the future.

Viracor Eurofins has launched CMV Resistance:Letermovir, a cytomegalovirus gene sequencing assay for the detection of resistance to Prevymis (letermovir), an antiviral for use in adult hematopoietic stem cell transplant patients. The assay is available as a standalone test or as a complete panel with the other CMV drugs as CMV Resistance: Letermovir, Ganciclovir, Foscarnet, Cidofovir. Viracor Eurofins said that resistance to Prevymis has not been detected in treatment-naive patients, but noted that clinical trials have shown that resistance can develop in the UL56 gene after exposure for some HSCT patients. 

Fluidic Analytics has announced the launch of its Fluidity One system, which offers researchers the ability to observe protein behavior by measuring the size and concentrations in their native state without the need for surfaces or matrices. Based on the firm's fluidic separation and detection technology, the system analyses protein in solution and in their natural state using microfluidic diffusional sizing. The tool uses as little as 50 nanograms and produces results in less than 10 minutes. 

Asuragen announced the CE marking and launch of its QuantideX NGS DNA Hotspot 21 Kit, a targeted next-generation sequencing panel to detect variants across a multitude of tumor types. By screening for the most commonly observed variants in a simplified workflow, the research-use-only kit addresses current clinical and laboratory challenges regarding NGS testing such as long time-to-result, high assay complexiity, and lengthy data interpretation.

The assay includes the firm's cGMP manufactured, end-to-end NGS-in-a-box design, providing the reagents needed to prepare sequencing-ready libraries in as little as 24 hours. The firm's bioinformatics software examines whether enough amplifiable DNA exists.